{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:05:26Z","timestamp":1784696726542,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 153099"],"award-info":[{"award-number":["PJT 153099"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 123431"],"award-info":[{"award-number":["MOP 123431"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006126","name":"The Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2024.09.021","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T16:44:54Z","timestamp":1727714694000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing 129Xe multi-breath washout MRI response to elexacaftor\/tezacaftor\/ivacaftor intervention in pediatric CF"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-7536","authenticated-orcid":false,"given":"Faiyza","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samal","family":"Munidasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Zanette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Braganza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-9579","authenticated-orcid":false,"given":"Renee","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pier","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-188X","authenticated-orcid":false,"given":"Giles","family":"Santyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2024.09.021_bib0001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr Opin Pediatr"},{"issue":"8","key":"10.1016\/j.jcf.2024.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.021_bib0003","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of lumacaftor\u2013ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in phe508del homozygous patients with cystic fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.021_bib0004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MCP.0000000000000515","article-title":"The lung clearance index as a monitoring tool in cystic fibrosis","volume":"24","author":"Perrem","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.09.021_bib0005","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201610-2158OC","article-title":"Progression of lung disease in preschool patients with cystic fibrosis","volume":"195","author":"Stanojevic","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.021_bib0006","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jcf.2020.05.010","article-title":"Changes in LCI in F508DEL\/F508DEL patients treated with lumacaftor\/ivacaftor: results from the prospect study","volume":"19","author":"Shaw","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.021_bib0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral Lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.021_bib0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.rmed.2009.01.025","article-title":"Lung clearance index in the assessment of airways disease","volume":"103","author":"Horsley","year":"2009","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.09.021_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcf.2016.07.008","article-title":"Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients","volume":"16","author":"Thomen","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.021_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jcf.2019.03.005","article-title":"A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: potential as a biomarker for multi-site trials","volume":"18","author":"Couch","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.09.021_bib0011","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1164\/rccm.201611-2228LE","article-title":"Correlation of lung clearance index with hyperpolarized 129Xe magnetic resonance imaging in pediatric subjects with cystic fibrosis","volume":"196","author":"Kanhere","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2024.09.021_bib0012","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00247-016-3672-1","article-title":"Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis","volume":"46","author":"Walkup","year":"2016","journal-title":"Pediatr Radiol"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02188-2018","article-title":"Hyperpolarised 129Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis","volume":"53","author":"Rayment","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.09.021_bib0014","series-title":"North American Cystic Fibrosis Conference","article-title":"Hyperpolarized 129Xe pulmonary MRI and multiple-breath washout to measure response to elexacaftor-tezacaftor-ivacaftor therapy in children","author":"Diamond","year":"2023"},{"key":"10.1016\/j.jcf.2024.09.021_bib0015","series-title":"North American Cystic Fibrosis Conference","article-title":"Response in imaging and lung function outcomes in the HyPOINT study","author":"Ratjen","year":"2023"},{"issue":"20","key":"10.1016\/j.jcf.2024.09.021_bib0016","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.3390\/jcm11206160","article-title":"Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after elexacaftor\/tezacaftor\/ivacaftor: an observational study","volume":"11","author":"Goralski","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.09.021_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mrm.10206","article-title":"Quantitative measurement of regional lung ventilation using3He MRI","volume":"48","author":"Deninger","year":"2002","journal-title":"Magn Reson Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.09.021_bib0018","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1152\/japplphysiol.00378.2013","article-title":"Quantification of regional fractional ventilation in human subjects by measurement of hyperpolarized3He washout with 2D and 3D MRI","volume":"116","author":"Horn","year":"2014","journal-title":"J Appl Physiol"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.021_bib0019","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/mrm.27234","article-title":"Effect of T1 relaxation on ventilation mapping using hyperpolarized 129 Xe multiple breath wash-out imaging","volume":"80","author":"Morgado","year":"2018","journal-title":"Magn Reson Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.021_bib0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/mrm.28099","article-title":"Assessing the feasibility of hyperpolarized 129 Xe multiple-breath washout MRI in pediatric cystic fibrosis","volume":"84","author":"Couch","year":"2019","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.jcf.2024.09.021_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.28638","article-title":"Intra - and inter-visit repeatability of 129 xenon multiple-breath washout MRI in children with stable cystic fibrosis lung disease","author":"Alam","year":"2023","journal-title":"J Magn Reson Imaging"},{"issue":"8","key":"10.1016\/j.jcf.2024.09.021_bib0022","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.09.021_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.021_bib0024","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/mrm.29566","article-title":"Inter- and intravisit repeatability of free-breathing MRI in pediatric cystic fibrosis lung disease","volume":"89","author":"Munidasa","year":"2023","journal-title":"Magn Reson Med"},{"issue":"24","key":"10.1016\/j.jcf.2024.09.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2024.09.021_bib0026","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-023-09912-6","article-title":"Effect of CFTR modulator therapy with elexacaftor\/tezacaftor\/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients","author":"Klime\u0161","year":"2023","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.021_bib0027","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2014A comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.021_bib0028","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.230084","article-title":"Lung function in patients with cystic fibrosis before and during cftr-modulator therapy using 3D ultrashort echo time MRI","volume":"308","author":"Heidenreich","year":"2023","journal-title":"Radiology"},{"issue":"21","key":"10.1016\/j.jcf.2024.09.021_bib0029","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.3390\/jcm10214884","article-title":"Lung clearance index in children with cystic fibrosis during pulmonary exacerbation","volume":"10","author":"Walicka-Serzysko","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.09.021_bib0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1152\/japplphysiol.01274.2013","article-title":"Slow and fast lung compartments in cystic fibrosis measured by nitrogen multiple-breath washout","volume":"117","author":"Gustafsson","year":"2014","journal-title":"J Appl Physiol 2014"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:09:53Z","timestamp":1762553393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199324017892"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.021","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing 129Xe multi-breath washout MRI response to elexacaftor\/tezacaftor\/ivacaftor intervention in pediatric CF","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}